ProNAi: ASCO 2016 (ProNAi) - Jul 2, 2016 - "PNT2258 as a single-agent resulted in clinically significant, durable responses in recurrent or treatment refractory NHL, including in four subjects with DLBCL: Overall response rate of 46.2% in the entire study population of 13 subjects, Noteworthy responses (CR, PR) and durable SD was also observed in follicular lymphoma subjects"; "Six subjects were progression free at 12 months; PFS extended to 2 years and beyond in four subjects: Five of the six subjects who were progression free at 12 months with PNT2258 were relapsed (not refractory) at study entry and had responded with their last prior therapy with a median time to treatment failure (TTF) of 48 months (4 yrs), range 23.7-87.6 months, All four responding DLBCL subjects had received 1 or 2 prior therapies"; "PNT2258 was safe and well tolerated in these NHL subjects and was administered for extended periods without evidence of cumulative toxicity for 2 years and longer"
P2 data • Diffuse Large B Cell Lymphoma • Non-Hodgkin's Lymphoma • Oncology
|